Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
"Clinical trials gave us time": A daughter’s tribute to her mother’s courage
When Kate Shin’s mother faced rectal cancer, clinical trials gave them precious time together. Now, Kate shares her story to encourage access to screening and innovative care, including clinical trials.
Blue Hope Bash Celebrates Craig Melvin & Lindsay Czarniak for Commitment to Colorectal Cancer Advocacy
The Colorectal Cancer Alliance’s 2025 Blue Hope Bash in Washington, D.C., raised $2.1 million for colorectal cancer awareness, research, and patient support.
Remembering Alison Friedman: A champion for access, equity, and hope
The Colorectal Cancer Alliance mourns the passing of Alison Kiehl Friedman, a tireless advocate, policy leader, board member, mom, wife, and beloved member of our community, whose impact will continue to shape our mission for years to come.